newsfilter
← Latest News
Business Wire·

NeoGenomics Reports Third Quarter 2026 Results

Total revenue increased 11% YoY to $209 million Clinical services revenue grew 13%, with NGS revenue growth of 29% Company raises full-year 2026 revenue and adjusted EBITDA guidance NeoGenomics, Inc. (NASDAQ:NEO)